**Background of DHRS2 Antibody**
DHRS2 (short-chain dehydrogenase/reductase family member 2) is a NADPH-dependent enzyme belonging to the short-chain dehydrogenase/reductase (SDR) superfamily. It is implicated in cellular processes such as retinoid metabolism, redox homeostasis, and cell differentiation. DHRS2 acts as a retinaldehyde reductase, converting retinaldehyde to retinol, and may regulate retinoic acid signaling, which is critical for development, immune function, and tissue homeostasis. Dysregulation of DHRS2 has been linked to diseases, including cancers, where it may act as a tumor suppressor or oncogene depending on context.
Antibodies targeting DHRS2 are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect DHRS2 in tissues or cell lines. Research utilizing DHRS2 antibodies has revealed its tissue-specific expression patterns, such as high levels in the liver, kidney, and epithelial cells, and its downregulation in certain cancers (e.g., gastric, colorectal). These antibodies also aid in exploring DHRS2's role in oxidative stress response and its interaction with signaling pathways like Wnt/β-catenin.
Recent studies highlight DHRS2's potential as a biomarker or therapeutic target, driving demand for validated, high-specificity antibodies. Commercial DHRS2 antibodies are typically raised against peptide epitopes and validated for cross-reactivity across species (human, mouse, rat). Ongoing research focuses on clarifying DHRS2's mechanistic roles in disease and development, underscoring the continued relevance of DHRS2 antibodies in biomedical studies.